Myriad Genetics, Inc., Selects Topin & Associates to Market OnDose® Dose Optimization Technology

CHICAGO – May 24, 2011 – Myriad Genetics, Inc., has selected Topin & Associates (topin.com) to support the ongoing marketing of OnDose Dose Optimization Technology to the oncology marketplace. OnDose is Myriad Genetics’ seventh molecular diagnostic product and an important entry in its personalized medicine product line. It utilizes proprietary technology to measure a patient’s exposure to the chemotherapy drug 5-Fluorouracil (5-FU), providing information with which a physician can optimize the dose of 5-FU to help maximize efficacy and reduce toxicity. Topin & Associates, along with its